Handcuffing the culprit cancer: Immunotherapy for cold tumors with trispecific antibody

The recent discovery of “bispecific antibodies” has led to the development of effective immunotherapies against various cancers. Researchers have constructed a protein made up of anti-CD16, -IL-15, and -CD19 motifs, specifically designed to capture CD19-positive cancer cells and redirect them to natural killer (NK) cells. This protein also enhances the proliferation, homeostasis, activation, and survival of NK cells. This concoction has shown to induce killing of cancer cells in both cell cultures and in mouse models.
Go to Source